Evidence map›Paper›PMID 29589833›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2018

Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study

Kenji Matsumoto, Shin Fujisawa, Taiki Ando, Megumi Koyama, Satoshi Koyama, Yoshimi Ishii, Ayumi Numata, Wataru Yamamoto, Kenji Motohashi, Maki Hagihara and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kenji MatsumotoYokohama City University Faculty of Medicine, Department of Hematology and Clinical Immunology, Yokohama, Japan
Shin FujisawaYokohama City University Faculty of Medicine, Department of Hematology, Yokohama, Japan
Taiki AndoYokohama City University Faculty of Medicine, Department of Hematology, Yokohama, Japan
Megumi KoyamaKanagawa Cancer Center, Clinic of Medical Oncology, Yokohama, Japan
Satoshi KoyamaKanagawa Cancer Center, Clinic of Hematology, Yokohama, Japan
Yoshimi IshiiYokohama City University Faculty of Medicine, Department of Hematology, Yokohama, Japan
Ayumi NumataKanagawa Cancer Center, Clinic of Medical Oncology, Yokohama, Japan
Wataru YamamotoKanagawa Cancer Center, Clinic of Medical Oncology, Yokohama, Japan
Kenji MotohashiYokohama City University Faculty of Medicine, Department of Hematology, Yokohama, Japan
Maki HagiharaYokohama City University Faculty of Medicine, Department of Hematology and Clinical Immunology, Yokohama, Japan
Hideaki NakajimaYokohama City University Faculty of Medicine, Department of Hematology and Clinical Immunology, Yokohama, Japan

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Useful prognostic biomarkers for diffuse large B-cell lymphoma (DLBCL) patients have been reported. To determine the prognostic value of hemoglobin (Hb) level in DLBCL patients, we performed a retrospective study. Materials and Methods: We evaluated disease outcome, progression-free survival (PFS), overall survival as the endpoint, and clinical and laboratory factors affecting the outcome of 185 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy during 2004-2014. Results: The study group included 121 men and 64 women with a median age of 66 years minimum-maximum: 21-83 years. In univariate analysis, factors independently associated with worse PFS were Eastern Cooperative Oncology Group performance status ≥2, Ann Arbor stage III or IV, anemia with Hb levels of <10 g/dL, and serum albumin of <3.5 g/dL. In multivariate analysis, anemia with Hb levels of <10 g/dL and Ann Arbor stage III or IV were found to be international index-independent prognostic factors (hazard ratio: 2.4; p=0.04). Conclusion: Anemia is an independent prognostic marker of poor outcome in DLBCL patients. Hb can be an easily available prognostic marker for risk stratification in these patients.

Indexed as

AdultAgedAged, 80 and overAnemiaDisease-Free SurvivalFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultAnemiaDiffuse large B-cell lymphomaHemoglobin

Identifiers

PMID29589833
PMCPMC6110437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.